Concord Biotech has released its Investor Presentation for the second quarter and half year ended September 30, 2026. The company reported a strong year-on-year revenue growth of 25% for Q2FY27. Key highlights include expansion into the dermatology segment with the launch of ‘Inspira’, receipt of two ANDA approvals, and successful completion of global regulatory inspections. Margins were marginally impacted by input costs and product mix changes.
Concord Biotech Presents Q2 & H1 FY27 Results
Concord Biotech Limited has issued an investor presentation detailing its unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2026. The company highlighted a robust year-on-year revenue growth of 25% for Q2FY27, driven by broad-based performance across product categories and geographies.
Key Business Developments
Significant strategic moves during the quarter include the launch of Inspira, a new dermatology division, marking Concord Biotech’s expansion into this segment. The company also received two ANDA approvals for Tofacitinib and MMF OS, expected to enhance market reach in the US and other regulated markets. Furthermore, the company successfully completed global regulatory inspections, including a USFDA inspection at its Unit II formulation facility in Valthera, reinforcing its global compliance standards.
Financial Performance Insights
While revenue saw strong growth, the company noted that margins were marginally impacted due to higher input costs and a change in product mix. The presentation also included financial highlights for Q2 and H1 FY27, showcasing consolidated revenue, EBITDA, and PAT figures, alongside Gross Profit Margin, EBIDTA Margin, and PAT Margin trends.
Shareholder Value and Future Outlook
In line with its commitment to shareholder value, Concord Biotech approved a 1:1 bonus share issue. The management expressed confidence in delivering sustainable long-term growth, supported by a strong compliance track record, a differentiated product portfolio, and expanding customer relationships.
Source: BSE
